Use of drotrecogin alfa (activated) in older patients with severe sepsis

Pharmacotherapy

Volumn 26, Issue 4, 2006, Pages 533-538

  Alexander, Sherri L ^a   Ernst, Frank R ^b  

^a GENENTECH INC   (United States)

^b ELI LILLY AND COMPANY   (United States)

Author keywords

Cost effectiveness; Critical care; Drotrecogin alfa (activated); Efficacy; Elderly; Ethics; ICU; Older patients; Resource utilization; Safety; Severe sepsis

Indexed keywords

ANTICOAGULANT AGENT; CLOPIDOGREL; DROTRECOGIN; FIBRINOGEN RECEPTOR ANTAGONIST; HYPERTENSIVE FACTOR; LOW MOLECULAR WEIGHT HEPARIN; WARFARIN;

ADULT; AGE; AGED; AGING; ANTICOAGULATION; ARTICLE; BLEEDING; BRAIN HEMORRHAGE; CLINICAL TRIAL; COST EFFECTIVENESS ANALYSIS; DEATH; DISEASE SEVERITY; DRUG APPROVAL; DRUG COST; DRUG EFFICACY; DRUG INDICATION; DRUG SAFETY; DRUG USE; ETHICS; EVALUATION; FOOD AND DRUG ADMINISTRATION; HEALTH CARE UTILIZATION; HIGH RISK PATIENT; HUMAN; INTENSIVE CARE; INTENSIVE CARE UNIT; MONEY; PERCEPTION; QUALITY ADJUSTED LIFE YEAR; SEPSIS; SURVIVAL; THROMBOEMBOLISM;

AGED; AGED, 80 AND OVER; ANTI-INFECTIVE AGENTS; CLINICAL TRIALS; COST-BENEFIT ANALYSIS; ETHICS, CLINICAL; HUMANS; INTENSIVE CARE; PROTEIN C; RECOMBINANT PROTEINS; SEPSIS;

EID: 33645696021     PISSN: 02770008     EISSN: None     Source Type: Journal    
DOI: 10.1592/phco.26.4.533     Document Type: Article

References (29)

1. Angus DC, Linde-Zwirble WT, Lidicker J, et al. Epidemiology of severe sepsis: analysis of incidence, outcome, and associated costs of care. Crit Care Med 2001;29:1303-10.
2. Rivers E, Nguyen B, Havstad S, et al. Early goal directed therapy in the treatment of severe sepsis and septic shock. N Engl J Med 2001;345:1368-77.
3. Van den Berghe G, Wouters P, Weckers F, et al. Intensive insulin therapy in critically ill patients. N Engl J Med 2001;345:1359-67.
4. Annane D, Bellisant E, Bollaert PE, et al. Corticosteroids for severe sepsis and septic shock: a systematic review and meta-analysis. BMJ 2004;329:480-9.
5. Bernard GB, Vincent JL, Laterre PF, et al. Efficacy and safety of recombinant human activated protein C for severe sepsis. N Engl J Med 2001;344:699-709.
6. Ely EW, Angus DC, Williams MD, Bates B, Qualy R, Bernard GR. Drotrecogin alfa (activated) treatment of older patients with severe sepsis. Clin Infect Dis 2003;37:187-95.
7. Brown DL. Deaths associated with platelet glycoprotein IIb/IIIa inhibitor treatment. Heart 2003;89:535-7.
8. Macie C, Forbes L, Foster GA, Douketis JD. Dosing practices and risk factors for bleeding in patients receiving enoxaparin for the treatment of an acute coronary syndrome. Chest 2004;125:1616-21.
9. Beyth RJ, Quinn L, Landefeld CS. A multicomponent intervention to prevent major bleeding complications in older patients receiving warfarin. Ann Intern Med 2000;133:687-95.
10. Wittkowsky AK, Whitely KS, Devine EB, Nutescu E. Effect of age on international normalized ratio at the time of major bleeding in patients treated with warfarin. Pharmacotherapy 2004;24:600-5.
11. Angus DC, Linde-Zwirble WT, Clermont G, et al. Cost-effectiveness of drotrecogin alfa (activated) in the treatment of severe sepsis. Crit Care Med 2003;31:1-11.
12. Fowler RA, Hill-Popper M, Stasinos J, Petrou C, Sanders GD, Garber AM. Cost-effectiveness of recombinant human activated protein C and the influence of severity of illness in the treatment of patients with severe sepsis. J Crit Care 2003;18:181-91.
13. Manns BJ, Lee H, Doig JC, Johnson D, Donaldson C. An economic evaluation of activated protein C treatment for severe sepsis. N Engl J Med 2002;347:993-1000.
14. Schmidt G, Bates B, McCollam JS. Clinical use of drotrecogin alfa (activated): Patients treated in MERCURY differ from those in PROWESS [abstr]. Crit Care Med 2003;31(suppl 12):A116.
15. Quap CW, Tran JI, Jackson A, Ham CW, Gupta V. The use of recombinant human activated protein C (RhAPC, drotrecogin alfa (activated)) in the management of patients with sepsis in the community hospital setting [abstr]. Crit Care Med 2002;30(suppl 12):A103.
16. Miles W, Sturdevant M, Huynh T, et al. A comparison of drotrecogin alfa (activated) in medical and surgical patients with severe sepsis [abstr]. Crit Care Med 2003;31 (suppl 12):A128.
17. Gerlach AT, Shirk MB, Swerlein A. Comparison of outcomes with drotrecogin alfa [activated] pre and post prescriber feedback [abstr]. Crit Care Med 2003;31(suppl 12):A115.
18. McKnight RL, Harakh VD, Scheibel FB. Application of physician derived and pharmacist implemented protocol for the use of drotrecogin alfa (Xigris®) in patients with severe sepsis in a rural, tertiary care university hospital [abstr]. Crit Care Med 2003;31(suppl 12):A115.
19. Swerlein A, Conty W, McCluskey C. Initial experience with drotrecogin alfa (activated) in two large tertiary care facilities [abstr]. Crit Care Med 2002;30(suppl 12):A104.
20. Marie A, Nadeau L, Carpenter C, et al. An evaluation of drotrecogin alfa (DA) therapy [abstr]. Crit Care Med 2003;31(suppl 12):A115.
21. Castelli EE, Culley CM, Fink MP. Incidence of coagulopathy, bleeding, and mortality in drotrecogin alfa (activated)-treated patients [abstr]. Crit Care Med 2003;31(suppl 12):A122.
22. Chapital A, Yu M, Conde A, Wang J. Effect of activated protein C on peripheral circulation in septic shock patients [abstr]. Crit Care Med 2002;30(suppl 12):A103.
23. Wittbrodt E, Rose C. Experience with drotrecogin alfa activated (DAA) in a tertiary care hospital [abstr]. Crit Care Med 2002;30(suppl 12):A104.
24. Laterre P-F, Levy H, Clermont G, et al. Hospital mortality and resource use in subgroups of the recombinant human activated protein C worldwide evaluation in severe sepsis (PROWESS) trial. Crit Care Med 2004;32(11):2207-18.
25. Angus DC, Barnato AE, Linde-Zwirble WT, et al. Use of intensive care at the end of life in the US. Crit Care Med 2004;32:638-43.
26. Snyder L, Leffler C, for the Ethics and Human Rights Committee, American College of Physicians. Ethics manual: fifth edition. Ann Intern Med 2005;142:560-82.
27. Somme D, Maillet JM, Gisselbrecht M, Novara A, Ract C, Fagon JY. Critically ill old and the oldest-old patients in intensive care: short- and long-term outcomes. Intensive Care Med 2003;29:2137-43.
28. Rentz AM, Halpern MT, Bowder R. The impact of candidemia on length of hospital stay, outcomes, and overall cost of illness. Clin Infect Dis 1998;27:781-8.
29. Esteban A, Anzueto A, Frutos-Vivar F, et al. Outcome of older patients receiving mechanical ventilation. Intensive Care Med 2004;30:639-46.